Cargando…
Increased SYK activity is associated with unfavorable outcome among patients with acute myeloid leukemia
Recent discoveries have led to the testing of novel targeted therapies for the treatment of acute myeloid leukemia (AML). To better inform the results of clinical trials, there is a need to identify and systematically assess biomarkers of response and pharmacodynamic markers of successful target eng...
Autores principales: | Boros, Katalin, Puissant, Alexandre, Back, Morgan, Alexe, Gabriela, Bassil, Christopher F., Sinha, Papiya, Tholouli, Eleni, Stegmaier, Kimberly, Byers, Richard J., Rodig, Scott J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4694851/ https://www.ncbi.nlm.nih.gov/pubmed/26315286 |
Ejemplares similares
-
SYK Regulates mTOR Signaling in AML
por: Carnevale, Julia, et al.
Publicado: (2013) -
Targeting MTHFD2 in acute myeloid leukemia
por: Pikman, Yana, et al.
Publicado: (2016) -
Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase
por: Weisberg, Ellen L., et al.
Publicado: (2017) -
Hoxa9 and Meis1 Cooperatively Induce Addiction to Syk Signaling by Suppressing miR-146a in Acute Myeloid Leukemia
por: Mohr, Sebastian, et al.
Publicado: (2017) -
Derepression of the Iroquois Homeodomain Transcription Factor Gene IRX3 Confers Differentiation Block in Acute Leukemia
por: Somerville, Tim D.D., et al.
Publicado: (2018)